Lack of metabolic effects of cholecystokinin on hepatocytes

Authors

  • Louis J. Kost,

    1. Gastroenterology Research Unit and Digestive Diseases Core Center, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905
    Search for more papers by this author
  • Gregory J. Gores,

    1. Gastroenterology Research Unit and Digestive Diseases Core Center, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905
    Search for more papers by this author
  • John M. Sayles,

    1. Gastroenterology Research Unit and Digestive Diseases Core Center, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905
    Search for more papers by this author
  • Laurence J. Miller,

    1. Gastroenterology Research Unit and Digestive Diseases Core Center, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905
    Search for more papers by this author
  • John J. Lemasters,

    1. Department of Cell Biology and Anatomy, School of Medicine, The University of North Carolina, Chapel Hill, NC 27599–7090
    Search for more papers by this author
  • Brian Herman,

    1. Department of Cell Biology and Anatomy, School of Medicine, The University of North Carolina, Chapel Hill, NC 27599–7090
    Search for more papers by this author
  • Nicholas F. Larusso M.D.

    Professor of Medicine, Corresponding author
    1. Gastroenterology Research Unit and Digestive Diseases Core Center, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905
    • Associate Professor of Biochemistry and Molecular Biology, Gastroenterology Unit, Mayo Clinic, Rochester, MN 55905
    Search for more papers by this author

Abstract

We previously reported that the liver was the major organ that extracts small, biologically active, circulating forms of cholecystokinin. Although our work indicated extensive degradation of cholecystokinin extracted from plasma during its transit across the hepatocyte, it was unclear whether cholecystokinin might also have a physiological effect on this cell before its intracellular degradation. Therefore we tested the hypothesis that cholecystokinin has a direct biological effect on hepatocytes. Using freshly isolated or cultured hepatocytes, we studied whether cholecystokinin-octapeptide alters protein synthesis, affects amino acid transport or influences cytosolic free calcium concentrations. Using liver slices, we also determined the effect of cholecystokinin-octapeptide on cyclic nucleotide levels. Cholecystokininoctapeptide, up to a concentration of 1 μmol/L, had no effect on the incorporation of radiolabeled amino acids into total hepatocyte protein; in contrast, comparable molar amounts of insulin stimulated protein synthesis by as much as 37% (ED50 = 1.5 × 10−10 mol/L). Although insulin and glucagon stimulated the transport into hepatocytes of 14C-α-aminoisobutyric acid, a nonmetabolizable amino acid analog, cholecystokinin-octapeptide had no effect. Cholecystokinin-octapeptide also did not affect either the concentration of calcium in individual hepatocytes, as measured by digitized video microscopy using Fura-2, or the levels of cyclic AMP or cyclic GMP in liver slices. Our results show that cholecystokinin has no effect on protein synthesis, on amino acid transport or on hepatocyte calcium and cyclic nucleotide levels. These and our previous data suggest that the primary outcome of hepatic extraction of cholecystokinin is hormone degradation. (HEPATOLOGY 1990;12:301–305).

Ancillary